• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Opportunities for enhancing efficiency and reducing cost in large scale disease prevention trials: a statistical perspective.

作者信息

Prentice R L

机构信息

Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA. 98104.

出版信息

Stat Med. 1990 Jan-Feb;9(1-2):161-70; discussion 170-2. doi: 10.1002/sim.4780090123.

DOI:10.1002/sim.4780090123
PMID:2345832
Abstract

Randomized intervention trials play an important role in the identification of practical approaches to reducing major chronic diseases in our society. Very few such trials are likely to be possible, however, in coming years unless we adopt procedures less demanding and less costly than those used in the past. Towards this end some elements of an efficient prevention trial are discussed, including aspects of study design, criteria for eligibility and exclusion, procedures for data collection, follow-up, endpoint ascertainment, and data analysis, and for ancillary studies. For example, possibilities for enhancing efficiency in the use of endpoint events include the selection of an appropriately weighted test statistic, the use of case-control or case-cohort sampling procedures in the processing of covariate data and specimens, and the notion of replacing a disease endpoint by an earlier or less expensive surrogate endpoint. Ideas for enhancing the efficiency of prevention trials will be illustrated in the context of a proposed Dietary Fat Intervention Trial for disease prevention in women.

摘要

相似文献

1
Opportunities for enhancing efficiency and reducing cost in large scale disease prevention trials: a statistical perspective.
Stat Med. 1990 Jan-Feb;9(1-2):161-70; discussion 170-2. doi: 10.1002/sim.4780090123.
2
Aspects of the science of cancer prevention trials: lessons from the conduct and planning of clinical trials of a low-fat diet intervention among women.癌症预防试验科学的若干方面:女性低脂饮食干预临床试验实施与规划的经验教训
Prev Med. 1991 Jan;20(1):147-57. doi: 10.1016/0091-7435(91)90015-v.
3
Efficient use of endpoints in clinical trials: a clinical perspective.临床试验中终点指标的有效应用:临床视角
Stat Med. 1990 Jan-Feb;9(1-2):155-60. doi: 10.1002/sim.4780090122.
4
Analysis of the costs of a large prevention trial.一项大型预防试验的成本分析。
Control Clin Trials. 1990 Apr;11(2):129-46. doi: 10.1016/0197-2456(90)90006-n.
5
Statistical design of the Women's Health Trial.妇女健康试验的统计设计
Control Clin Trials. 1988 Jun;9(2):119-36. doi: 10.1016/0197-2456(88)90033-5.
6
On Enrichment Strategies for Biomarker Stratified Clinical Trials.关于生物标志物分层临床试验的富集策略
J Biopharm Stat. 2018;28(2):292-308. doi: 10.1080/10543406.2017.1379532. Epub 2017 Oct 30.
7
Recruitment strategy cost and impact on minority accrual to a breast cancer prevention trial.招募策略的成本及其对乳腺癌预防试验中少数民族入组的影响。
Clin Trials. 2013 Apr;10(2):292-9. doi: 10.1177/1740774512471452. Epub 2013 Jan 15.
8
Efficient means of studying ancillary questions in clinical trials.在临床试验中研究辅助问题的有效方法。
Stat Med. 1990 Jan-Feb;9(1-2):97-100. doi: 10.1002/sim.4780090116.
9
Cost and efficiency in clinical trials: the U.S. Physicians' Health Study.
Stat Med. 1990 Jan-Feb;9(1-2):29-33. doi: 10.1002/sim.4780090109.
10
Dietary fat and breast cancer risk: the feasibility of a clinical trial of breast cancer prevention.膳食脂肪与乳腺癌风险:一项乳腺癌预防临床试验的可行性
Lipids. 1992 Oct;27(10):821-6. doi: 10.1007/BF02535857.

引用本文的文献

1
Development of a conceptual framework for defining trial efficiency.定义试验效率的概念框架的发展。
PLoS One. 2024 May 23;19(5):e0304187. doi: 10.1371/journal.pone.0304187. eCollection 2024.
2
Transfusion Decision Making in Pediatric Critical Illness.小儿危重症中的输血决策
Pediatr Clin North Am. 2017 Oct;64(5):991-1015. doi: 10.1016/j.pcl.2017.06.003.
3
Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.预先存在的少数耐药性 HIV-1 变异体、依从性和抗逆转录病毒治疗失败的风险。
J Infect Dis. 2010 Mar;201(5):662-71. doi: 10.1086/650543.
4
Optimising the economic efficiency of drug studies.优化药物研究的经济效率。
Pharmacoeconomics. 1992 Nov;2(5):371-87. doi: 10.2165/00019053-199202050-00005.